相关临床试验
212
23 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1904
进行中（未招募）
13
6.1%
已完成
123
58.0%
Enrolling By Invitation
1
0.5%
尚未招募
9
4.3%
招募中
23
10.8%
终止
9
4.3%
Unknown
31
14.6%
撤回
3
1.4%
暂无批准数据
- Long-term results from the Optimum (MUK Nine) trial show 70% of high-risk myeloma patients on personalised treatment were alive at six years, versus around 40% on standard therapy. - Progression-free survival at six years reached 54% with the risk-adapted approach, compared with 18% for patients receiving usual care. - The trial, led by The Institute of Cancer Research, combined a stem cell transplant with five existing NHS drugs, adapted to each patient's molecular disease biology. - Researchers found the MMProfiler SKY92 gene-expression test identifies high-risk patients who are currently missed, and it is now under regulatory evaluation for NHS use.
- Panakeia's PANProfiler Colorectal (MSI/MMR) software demonstrated 93.83% agreement with standard laboratory testing in the largest real-world, multi-site validation study of AI molecular profiling to date. - The AI software successfully returned results on 86.55% of cases across 1,243 colorectal cancer patients from three UK healthcare institutions, delivering molecular biomarker analysis in minutes rather than weeks. - Published in npj Digital Medicine, the study addresses critical gaps in molecular testing access, with national audits showing substantial proportions of eligible patients experience testing delays of several weeks. - The UKCA-marked software is now deployed in UK hospitals and selected for the MHRA's AI Airlock programme, positioning it for broader healthcare system implementation.
- The UK government is integrating clinical trial access into the NHS App, allowing brain tumour and rare cancer patients to search for and sign up to relevant trials automatically. - A new £32.3 million funding boost since July 2024 supports brain cancer research, including the establishment of national rare cancer leads and enhanced trial coordination. - The Brain Tumour Charity is co-funding ACT-BT, a University of Leeds-hosted initiative featuring a 10-expert panel to match patients with appropriate clinical trials across the UK. - Current brain tumour clinical trial participation remains critically low at just 12% of patients, representing the lowest recruitment levels among all cancer types in the UK.
- The UK DANTE phase III trial found that 80.2% of patients who stopped immunotherapy after 12 months maintained disease control, compared to 87.6% who continued treatment for two years or more. - The study represents the largest prospective trial to date evaluating optimal treatment duration for inoperable late-stage melanoma with immunotherapy drugs like pembrolizumab and nivolumab. - While promising, the trial was underpowered due to pandemic-related recruitment challenges, meaning two-year treatment should remain the current standard. - Quality of life analyses showed little difference between shorter and longer treatment durations, with cost-effectiveness studies currently underway.
- A phase 3 clinical trial led by the University of Leeds demonstrated that a second stem cell transplant followed by ixazomib maintenance therapy extends myeloma remission by seven months compared to standard care. - The ACCoRd trial treatment protocol combines autologous stem cell transplantation with targeted drugs thalidomide, dexamethasone, and ixazomib, offering patients improved quality of life compared to chemotherapy or long-term steroid use. - Ixazomib works by preventing protein breakdown in myeloma cells, causing toxic buildup while allowing healthy cells to grow, presenting a promising alternative for patients eligible for a second bone marrow transplant.
- The phase 2 PLATO-ACT4 trial demonstrated that reduced-dose intensity-modulated radiotherapy (IMRT) achieved comparable complete clinical response rates to standard dosing in early-stage anal cancer patients. - Patients receiving reduced-dose treatment experienced fewer grade 3+ toxicities (35% vs 46%), better treatment compliance, and improved sexual function scores at 6 months compared to standard dosing. - The breakthrough findings could transform clinical practice globally after 30 years of a "one-size-fits-all" approach, offering a shorter, kinder treatment option without compromising cure rates.
- Exploratory findings from the FOxTROT trial reveal that adding panitumumab to neoadjuvant FOLFOX chemotherapy significantly reduced recurrence and improved survival in patients with RAS/BRAF wild-type locally advanced colon cancer. - The combination therapy demonstrated impressive results with a 49% reduction in disease-free survival risk (HR, 0.51), 77% reduction in colon cancer death risk (HR, 0.23), and 64% improvement in overall survival (HR, 0.36) compared to FOLFOX alone. - These results provide the first evidence that anti-EGFR therapy can improve long-term cancer control in locally advanced colon cancer, validating molecular selection for targeted therapy in non-metastatic disease.
- The second annual London Biotechnology Show (#LBS25) builds on the success of its inaugural edition, which attracted over 3,000 attendees from 1,500 companies and featured 70+ sponsors and exhibitors. - This year's expanded event features a 4,000 square meter floor plan showcasing cutting-edge products and services from leading companies including Discovery Park, Merck, Microsoft, and AstraZeneca. - The show introduces a Hosted Buyer Programme offering pre-arranged one-to-one meetings to facilitate strategic partnerships and business growth opportunities. - An enhanced conference program will feature speakers from major organizations including Novo Nordisk, Pfizer, Bayer Pharmaceuticals, and the Medicines and Healthcare products Regulatory Agency discussing gene editing, regenerative medicine, and digital health innovations.
